EC approves Vertex’s Symkevi plus Kalydeco to treat CF in children aged 6-11 years

This article was originally published here

CF, a rare and life-shortening genetic disease, that affects around 75,000 people across the globe. It is a progressive and multi-system disease that damages the lungs, liver, GI

The post EC approves Vertex’s Symkevi plus Kalydeco to treat CF in children aged 6-11 years appeared first on Pharmaceutical Business review.